Research Article
Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value
Table 2
Baseline variables and laboratory findings for early and late stage lung cancer patients.
| | Variables | Early stage* (n = 23) | Late stage* (n = 107) | P |
| | Age (years) | 65.39 ± 14.52 | 64.11 ± 11.67 | 0.649 | | Male gender | 78.3% (18) | 49.5% (53) | 0.02 | | Smoking | 60.9% (14) | 42.1% (45) | 0.112 | | Hypertension | 21.7% (5) | 17.8% (19) | 0.767 | | Total cholesterol (mg/dL) | 197 ± 71 | 173 ± 42 | 0.469 | | Diabetes mellitus | 8.7% (2) | 9.3% (10) | 1.0 | | Body mass index (kg/m2) | 23.74 ± 4.52 | 22.39 ± 3.84 | 0.193 | | RBC count (×106/dL) | 4.37 ± 0.53 | 4.28 ± 1.39 | 0.770 | | WBC count (×103/dL) | 7.091 ± 2.54 | 7.504 ± 3.08 | 0.550 | | Platelet count (×104/dL) | 21.74 ± 7.95 | 24.22 ± 10.18 | 0.273 | | Creatinine (mg/dL) | 0.96 ± 0.22 | 1.03 ± 0.59 | 0.586 | | AST (IU/L) | 22 (19–30) | 27 (22–36) | 0.373 | | ALT (IU/L) | 18 (13–27) | 21 (16–36) | 0.169 | | Ac sugar (mg/dL) | 142.39 ± 54.38 | 129.18 ± 64.65 | 0.422 | | CEA (5 mg/mL) | 11.96 ± 22.24 | 92.24 ± 328.11 | 0.243 | | CD31+ CD42b− AN-V+ (counts/mL)† | 1086 (297–3348) | 716 (306–1872) | 0.158 | | CD31+ CD42b− AN-V− (counts/mL)† | 7935 (3434–23079) | 6546 (2685–13634) | 0.169 | | CD31+ CD42b+ AN-V+ (counts/mL)† | 19162 (5311–174196) | 15357 (6221–45201) | 0.407 | | CD31+ CD42b+ AN-V− (counts/mL)† | 46846 (17141–66585) | 22776 (12049–44329) | 0.031 |
|
|
Data are expressed as mean ± SD or % (number).
LC: lung cancer; RBC: white blood cell count; WBC: white blood cell count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CEA: carcinoembryonic antigen.
*Early stage: stages I, II, and IIIa (i.e., operable condition) lung cancer; late stage: stages IIIb and IV (inoperable) lung cancer.
†CD31+ CD42b− AN-V+: endothelial-derived apoptotic microparticle (MP); CD31+ CD42b− AN-V−: endothelial-derived activated MP; CD31+ CD42b+ AN-V+: platelet-derived apoptotic MP; CD31+ CD42b+ AN-V−: platelet-derived activated MP.
|
